Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | DN273 | — |
got second dose prior to the recommended six months; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 5-year-old male patient who received HAV (Havrix) (batch number DN273, expiry date 28-AUG-2026) for prophylaxis. Previously administered products included Havrix (recived 1st dose on 29-JUL-2024 with batch number: LM99N and expiry date: 04-MAR-2026). On 17-JAN-2025, the patient received the 2nd dose of Havrix. On 17-JAN-2025, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: got second dose prior to the recommended six months). The outcome of the drug dose administration interval too short was unknown. Additional Information: GSK receipt date: 21-JAN-2025 The licensed practitioner nurse reported that they administered to a Havrix vaccine, then 4 years old child, who was now 5 years old, roughly 10 days prior to the six months, prior to the recommended six months. The reporter had a question for second dose, and she just wanted to know was that an issue and did the patient need to be revaccinated. The patient received 2nd dose of Havrix vaccine earlier than the recommended interval, which led to shortening of the vaccination scheduled.